A Phase 1/2 interventional study of tafasitamab and lenalidomide in Non Hodgkins Lymphoma and Diffuse Large B-cell Lymphoma, sponsored by Incyte Biosciences Japan GK. Active, not recruiting at 23 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Incyte Biosciences Japan GK (part of Incyte Corporation) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing tafasitamab in Lymphoma, Large B-Cell, Diffuse — 3 open to participants now, 9 under way, 2 of them phase 3. tafasitamab · Lymphoma, Large B-Cell, Diffuse.
Among the 12 studies testing tafasitamab in Lymphoma, Large B-Cell, Diffuse, this one is the 6th largest by enrollment, is the only one that started in 2020, is one of 2 in phase 1/2, and was the 4th registered.
1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.
Browse Lymphoma, Large B-Cell, Diffuse studies →3 of the 12 studies testing tafasitamab in Lymphoma, Large B-Cell, Diffuse are open now, in 2 countries. Recruiting first, the newest first:
Paolo Caimi, MD · Sites in United States
Ages 18+
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea · Sites in Spain
Ages 18+
Brown University · Sites in United States
Ages 18+
By country, each count listing its studies:
tafasitamab: first FDA approval 2020 (MONJUVI), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 265 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 176 (66%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 3
First in 2016; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 72 is above the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.
Median enrollment 69 across the 12 interventional studies. Of the 3 that completed or were terminated, 3 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 12 have an industry lead sponsor. The 8 most frequent:
This study is registered under Incyte Biosciences Japan GK, one of the names counted as Incyte Corporation. Under that name alone:
Incyte Biosciences Japan GK is the lead sponsor of 6 studies on the registry; none are open to participants now.
15 studies in Lymphoma, Large B-Cell, Diffuse by Incyte Corporation: 1 open now, 5 under way, 2 of them phase 3. Of 10 finished, 5 (50%) have results posted.
Among the 15 studies in Lymphoma, Large B-Cell, Diffuse by Incyte Corporation, this one is the 6th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2020, is one of 5 in phase 1/2, and was the 10th registered.
Incyte Corporation’s Lymphoma, Large B-Cell, Diffuse studies by the year they started, since 2015.
1 of the studies testing tafasitamab in Lymphoma, Large B-Cell, Diffuse that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04978584M.D. Anderson Cancer CenterRituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study | 2027-01-16 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing tafasitamab in Lymphoma, Large B-Cell, Diffuse, from their registry updates:
Among Incyte Corporation’s 15 in Lymphoma, Large B-Cell, Diffuse:
This tab as a report to print or save as PDF → With an account.
This is an open-label, multicenter study to evaluate safety and tolerability, determine the RP2Ds of tafasitamab alone in Japanese participants with R/R NHL, or to evaluate efficacy and safety of tafasitamab in combination with lenalidomide in Japanese participants with R/R DLBCL, or tafasitimab in combination with lenalidomide plus R-CHOP in Japanese participants with previously untreated DLBC, or tafasitimab in combination with lenalidomide in Japanese participants with previously R/R DLBC.
1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.
This study's enrollment of 72 is above the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.
Browse Lymphoma, Large B-Cell, Diffuse studies →Incyte Biosciences Japan GK is the lead sponsor of 6 studies on the registry; none are open to participants now.
Compared within Lymphoma, Large B-Cell, Diffuse, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma, Non-Hodgkin. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Received at least 1 previous systemic therapy line for the treatment of NHL. At least 1 previous therapy line must have included a CD20-targeted therapy (eg, RTX).
Received at least 1, but no more than 3, previous systemic therapy lines for the treatment of DLBCL. At least 1 previous therapy line must have included a CD20-targeted therapy (eg, RTX).
Group 5 only: Participants must have:
In the opinion of investigator, the participant must:
Exclusion Criteria:
Groups 1, 3, 4a and 6 only: Participants who have:
Groups 1, 3 and 4a only: Previous treatment with CD19-targeted therapy (eg, CD19-CAR-T therapies, other CD19 mAbs including bispecific and ADCs).
Groups 2 and 6 only: Previous treatment with tafasitamab. Note: Participants in Groups 2 and 6 who have received previous CD19 directed therapy (other than tafasitamab) must have CD19-positive lymphoma confirmed by a taken after completing the prior CD19-targeted therapy.
Group 5 only: Participants who have:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dose-finding to evaluate the safety and tolerability and to determine the RP2Ds of single-agent tafasitamab in Japanese participants with NHL. Part 1 consists of 1 group (Group 1) to evaluate weight-based doses of tafasitamab.
Drug: tafasitamab
tafasitamab will be combined with lenalidomide (Group 3) or parsaclisib (Group 4a) in R/R DLBCL participants or lenalidomide plus R-CHOP (Group 5) in previously untreated DLBCL participants. Modified tafasitamab dosing when combined with lenalidomide (Group 2) in participants with R/R DLBCL will be evaluated to determine the recommended clinical dose. The dose of tafasitamab will be based on the weight-based RP2D that is deemed safe and tolerable in Part 1.
Drug: tafasitamab · Drug: lenalidomide · Drug: parsaclisib · Drug: R-CHOP
tafasitamab in combination with parsaclisib will be further evaluated in Group 4b at RP2D determined in Part 2
Drug: tafasitamab · Drug: parsaclisib
tafasitamiab in combination with lenalidomide will be further evaluated in Group 6 at RP2D determined in Part 2.
Drug: tafasitamab · Drug: lenalidomide
tafasitamab will be administered at protocol defined timepoints based on the groups participants are assigned.
Also known as: INCMOR00208, MOR00208, Xmab5574
lenalidomide will be administered orally at protocol defined timepoints based on the groups participants are assigned.
parsaclisib will be administered at protocol defined timepoints based on the groups participants are assigned.
R-CHOP is a combination regimen consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone. R-CHOP will be administered at protocol defined timepoints based on the groups participants are assigned.
Phase 1, Parts 1 and 2; Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE was defined as any new AE/worsening of an event from the first dose to 90 days (30 days until Amendment 3) after the last dose.
Time frame: up to 1066 days
Phase 1, Parts 1 and 2; Number of Participants With Any ≥Grade 3 TEAE
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. A TEAE was defined as any new AE/worsening of an event from the first dose to 90 days (30 days until Amendment 3) after the last dose. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 Grades 1 through 5. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.
Time frame: up to 1066 days
Phase 1, Part 1 and Part 2 (Groups 3, 4a, and 5); Number of Participants With Any Dose-limiting Toxicity (DLT)
A DLT was defined as the occurrence of any protocol-defined toxicity occurring up to and including Day 28 (Day 21 in Group 5 only), except those with a clear alternative explanation.
Time frame: up to 28 days
Phase 2, Part 4: Objective Response (OR) as Determined by an Independent Review Committee (IRC) According to Lugano Criteria
OR=percentage of participants with a complete response/complete metabolic response (CR/CMR) or partial response/partial metabolic response (PR/PMR). CR: (1) target nodes/nodal masses of lymph nodes/extralymphatic sites regressed to ≤1.5 centimeters (cm) in the longest dimension transverse diameter of lesion (LDi); (2) absence of non-measured lesions; (3) organ enlargement regressed to normal; (4) no new lesions; (5) normal bone marrow morphology; if indeterminate, immunohistochemistry negative. PR: (1) lymph nodes/extralymphatic sites: ≥50% decrease in the sum of the product of perpendicular diameters for multiple lesions of up to 6 target measurable nodes/extranodal sites; (2) absent/regressed non-measured lesions, no increase; (3) organ enlargement; spleen regressed by \>50% in length beyond normal; (4) no new lesions.
Time frame: up to 723 days
Phase 1, Parts 1 and 2; Cmax of Tafasitamab
Cmax was defined as the maximum observed plasma concentration of tafasitamab. Samples were collected as follows: Groups 1, 3, and 4a: Cycle 1 Day 1, preinfusion, immediately after tafasitamab infusion, 1 and 4 hours post-infusion (PI). Cycle 1 Day 2, 24 hours PI on Day 1. Cycle 1 Days 4, 8, 15, and 22, preinfusion; 1 hour PI. Cycles 2 and 3 Days 1, 22, preinfusion and 1 hour PI. Cycle 4 and beyond every 4 cycles (8, 12, etc.) Day 1, preinfusion. Safety follow-up/end of study visit, untimed sample. Group 2: Cycle 1 Days 1, 4, 8, and 15, preinfusion, 30 min PI. Cycles 2 and 3 Days 1 and 15, preinfusion and 30 min PI. Cycle 4-12 (every other cycle, i.e., Cycle 4, 6, 8, 12) Day 1, preinfusion and 30 min PI. Cycle 12 Day 28 and end of treatment, untimed sample. Group 5: Cycle 1 Day 1, preinfusion, immediately after tafasitamab infusion, 1 and 4 hours PI. Cycle 1 Day 2, 24 hours PI on Day 1. Cycle 1 Days 8 and 15, preinfusion and 1 hour PI. Cycles 2 and 3-6 Day 1, preinfusion and 1 hour PI.
Time frame: Cycle 1 Days 1, 4, 8, 15, 22; Cycles 2 and 3 Days 1 and 22; Cycle 4 and every 4 cycles thereafter (Cycles 8, 12, etc.) Day 1; End of Treatment
Phase 1, Parts 1 and 2; Cmin of Tafasitamab
Cmin was defined as the minimum observed plasma concentration of tafasitamab. Samples were collected as follows: Groups 1, 3, and 4a: Cycle 1 Day 1, preinfusion, immediately after tafasitamab infusion, 1 and 4 hours post-infusion (PI). Cycle 1 Day 2, 24 hours PI on Day 1. Cycle 1 Days 4, 8, 15, and 22, preinfusion; 1 hour PI. Cycles 2 and 3 Days 1, 22, preinfusion and 1 hour PI. Cycle 4 and beyond every 4 cycles (8, 12, etc.) Day 1, preinfusion. Safety follow-up/end of study visit, untimed sample. Group 2: Cycle 1 Days 1, 4, 8, and 15, preinfusion, 30 min PI. Cycles 2 and 3 Days 1 and 15, preinfusion and 30 min PI. Cycle 4-12 (every other cycle, i.e., Cycle 4, 6, 8, 12) Day 1, preinfusion and 30 min PI. Cycle 12 Day 28 and end of treatment, untimed sample. Group 5: Cycle 1 Day 1, preinfusion, immediately after tafasitamab infusion, 1 and 4 hours PI. Cycle 1 Day 2, 24 hours PI on Day 1. Cycle 1 Days 8 and 15, preinfusion and 1 hour PI. Cycles 2 and 3-6 Day 1, preinfusion and 1 hour PI.
Time frame: Cycle 1 Days 1, 4, 8, 15, 22; Cycles 2 and 3 Days 1 and 22; Cycle 4 and every 4 cycles thereafter (Cycles 8, 12, etc.) Day 1; End of Treatment
Phase 2, Part 4; Cmax of Tafasitamab
Cmax was defined as the maximum observed plasma concentration of tafasitamab.
Time frame: Cycle 1 Days 1, 4, and 15, preinfusion and 1 hour post-infusion. Cycles 2 and 3 Days 1 and 15, preinfusion and 1 hour post-infusion. Cycle 4 and every 4 cycles thereafter (Cycles 8, 12, etc.) Day 1, preinfusion. End of treatment, untimed sample
Phase 2, Part 4; Cmin of Tafasitamab
Cmin was defined as the minimum observed plasma concentration of tafasitamab.
Time frame: Cycle 1 Days 1, 4, and 15, preinfusion and 1 hour post-infusion. Cycles 2 and 3 Days 1 and 15, preinfusion and 1 hour post-infusion. Cycle 4 and every 4 cycles thereafter (Cycles 8, 12, etc.) Day 1, preinfusion. End of treatment, untimed sample
Phase 1, Part 2: Percentage of Participants With the Indicated Response Per Investigator Assessment of Response According to the Lugano Criteria
CR: (1) target nodes/nodal masses of lymph nodes/extralymphatic sites regressed to ≤1.5 cm in the longest dimension transverse diameter of lesion (LDi); (2) absence of non-measured lesions; (3) organ enlargement regressed to normal; (4) no new lesions; (5) normal bone marrow morphology; if indeterminate, immunohistochemistry negative. PR: (1) lymph nodes/extralymphatic sites: ≥50% decrease in the sum of the product of perpendicular diameters for multiple lesions of up to 6 target measurable nodes/extranodal sites; (2) absent/regressed non-measured lesions, no increase; (3) organ enlargement; spleen regressed by \>50% in length beyond normal; (4) no new lesions.
Time frame: up to approximately 6 years
Phase 1, Part 2: Percent Reduction in the Sum of the Products of Perpendicular Diameters for Multiple Lesions in up to 6 Target Measurable Nodes/Extranodal Sites Assessed by Computed Tomography as Per Investigator Assessment of Lugano Criteria Response
The sum of the products of the longest perpendicular diameters (SPD) was calculated by summing the products of the two longest perpendicular diameters for each target lesion or any extranodal lesion. Percent reduction in SPD from baseline in up to 6 target measurable nodes and extranodal sites assessed by computed tomography as per investigator assessment of response according to the Lugano criteria was calculated per assessment, and the highest reduction was analyzed.
Time frame: up to approximately 6 years
Phase 2, Part 4: Complete Response (CR) as Determined by an IRC According to Lugano Criteria
CR: (1) target nodes/nodal masses of lymph nodes/extralymphatic sites regressed to ≤1.5 cm in the longest dimension transverse diameter of lesion (LDi); (2) absence of non-measured lesions; (3) organ enlargement regressed to normal; (4) no new lesions; (5) normal bone marrow morphology; if indeterminate, immunohistochemistry negative.
Time frame: up to approximately 6 years
Phase 2, Part 4: Kaplan-Meier Estimate of Duration of Response (DOR) as Determined by an IRC According to Lugano Criteria
DOR was defined as the time from the first documented CR/CMR or PR/PMR as determined by an IRC according to the Lugano criteria until the date of the first documented disease progression or death due to any cause, whichever occurred first. CR: (1) target nodes/nodal masses of lymph nodes/extralymphatic sites regressed to ≤1.5 cm in the longest dimension transverse diameter of lesion (LDi); (2) absence of non-measured lesions; (3) organ enlargement regressed to normal; (4) no new lesions; (5) normal bone marrow morphology; if indeterminate, immunohistochemistry negative. PR: (1) lymph nodes/extralymphatic sites: ≥50% decrease in the sum of the product of perpendicular diameters for multiple lesions of up to 6 target measurable nodes/extranodal sites; (2) absent/regressed non-measured lesions, no increase; (3) organ enlargement; spleen regressed by \>50% in length beyond normal; (4) no new lesions.
Time frame: up to approximately 6 years
Phase 2, Part 4: Kaplan-Meier Estimate of Progression-free Survival (PFS) as Determined by an IRC
PFS was defined as the time from the date of the first dose of study treatment until the first documented disease progression as determined by an IRC according to the Lugano criteria or death due to any cause, whichever occurred first. Kaplan-Meier estimates indicate the percent probability of a participant being alive at the indicated time after treatment start.
Time frame: up to approximately 6 years
Phase 2, Part 4: Kaplan-Meier Estimate of Overall Survival
Overall survival was defined as defined as the time from the first dose of study treatment until death due to any cause. Kaplan-Meier estimates indicate the percent probability of a participant being alive at the indicated time after treatment start.
Time frame: up to approximately 6 years
Phase 2, Part 4: OR as as Per Investigator Assessment of Response According to the Lugano Criteria
OR=percentage of participants with a CR/CMR or PR/PMR. CR: (1) target nodes/nodal masses of lymph nodes/extralymphatic sites regressed to ≤1.5 cm in the longest dimension transverse diameter of lesion (LDi); (2) absence of non-measured lesions; (3) organ enlargement regressed to normal; (4) no new lesions; (5) normal bone marrow morphology; if indeterminate, immunohistochemistry negative. PR: (1) lymph nodes/extralymphatic sites: ≥50% decrease in the sum of the product of perpendicular diameters for multiple lesions of up to 6 target measurable nodes/extranodal sites; (2) absent/regressed non-measured lesions, no increase; (3) organ enlargement; spleen regressed by \>50% in length beyond normal; (4) no new lesions.
Time frame: up to approximately 6 years
Phase 2, Part 4: CR as Per Investigator Assessment of Response According to the Lugano Criteria
CR: (1) target nodes/nodal masses of lymph nodes/extralymphatic sites regressed to ≤1.5 cm in the longest dimension transverse diameter of lesion (LDi); (2) absence of non-measured lesions; (3) organ enlargement regressed to normal; (4) no new lesions; (5) normal bone marrow morphology; if indeterminate, immunohistochemistry negative.
Time frame: up to approximately 6 years
Phase 2, Part 4: DOR as Per Investigator Assessment of Response According to the Lugano Criteria
DOR was defined as the time from the first documented CR/CMR or PR/PMR as determined by an IRC according to the Lugano criteria until the date of the first documented disease progression or death due to any cause, whichever occurred first. CR: (1) target nodes/nodal masses of lymph nodes/extralymphatic sites regressed to ≤1.5 cm in the longest dimension transverse diameter of lesion (LDi); (2) absence of non-measured lesions; (3) organ enlargement regressed to normal; (4) no new lesions; (5) normal bone marrow morphology; if indeterminate, immunohistochemistry negative. PR: (1) lymph nodes/extralymphatic sites: ≥50% decrease in the sum of the product of perpendicular diameters for multiple lesions of up to 6 target measurable nodes/extranodal sites; (2) absent/regressed non-measured lesions, no increase; (3) organ enlargement; spleen regressed by \>50% in length beyond normal; (4) no new lesions.
Time frame: up to approximately 6 years
Phase 2, Part 4: PFS as Per Investigator Assessment of Response According to the Lugano Criteria
PFS was defined as the time from the date of the first dose of study treatment until the first documented disease progression as determined by an IRC according to the Lugano criteria or death due to any cause, whichever occurred first.
Time frame: up to approximately 6 years
Phase 2, Part 4: Number of Participants With Any TEAE
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE was defined as any new AE/worsening of an event from the first dose to 90 days (30 days until Amendment 3) after the last dose.
Time frame: up to approximately 6 years
Phase 2, Part 4: Number of Participants With Any ≥Grade 3 TEAE
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. A TEAE was defined as any new AE/worsening of an event from the first dose to 90 days (30 days until Amendment 3) after the last dose. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 Grades 1 through 5. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.
Time frame: up to approximately 6 years
| Milestone | Phase 1, Part 1, Group 1: Tafasitamab Monotherapy | Phase 1, Part 2, Group 2: Tafasitamab Plus Lenalidomide (LEN) | Phase 1, Part 2, Group 3: Tafasitamab Plus LEN | Phase 1, Part 2, Group 4a: Tafasitamab Plus Parsaclisib | Phase 1, Part 2, Group 5: Tafasitamab Plus LEN Plus R-CHOP | Phase 2, Part 4, Group 6: Tafasitamab Plus LEN |
|---|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 | 6 | 42 |
| Completed | 3 | 1 | 3 | 2 | 5 | 0 |
| Not completed | 3 | 5 | 3 | 4 | 1 | 42 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 1 | 7 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 0 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Priority given to next treatment | 0 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Ongoing | 3 | 5 | 1 | 2 | 0 | 33 |
An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE was defined as any new AE/worsening of an event from the first dose to 90 days (30 days until Amendment 3) after the last dose.
| Participants | Phase 1, Part 1, Group 1: Tafasitamab Monotherapy | Phase 1, Part 2, Group 2: Tafasitamab Plus Lenalidomide (LEN) | Phase 1, Part 2, Group 3: Tafasitamab Plus LEN | Phase 1, Part 2, Group 4a: Tafasitamab Plus Parsaclisib | Phase 1, Part 2, Group 5: Tafasitamab Plus LEN Plus R-CHOP |
|---|---|---|---|---|---|
| Phase 1, Parts 1 and 2; Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | 6 | 6 | 6 | 6 | 6 |
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. A TEAE was defined as any new AE/worsening of an event from the first dose to 90 days (30 days until Amendment 3) after the last dose. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 Grades 1 through 5. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.
| Participants | Phase 1, Part 1, Group 1: Tafasitamab Monotherapy | Phase 1, Part 2, Group 2: Tafasitamab Plus Lenalidomide (LEN) | Phase 1, Part 2, Group 3: Tafasitamab Plus LEN | Phase 1, Part 2, Group 4a: Tafasitamab Plus Parsaclisib | Phase 1, Part 2, Group 5: Tafasitamab Plus LEN Plus R-CHOP |
|---|---|---|---|---|---|
| Phase 1, Parts 1 and 2; Number of Participants With Any ≥Grade 3 TEAE | 2 | 3 | 5 | 4 | 6 |
A DLT was defined as the occurrence of any protocol-defined toxicity occurring up to and including Day 28 (Day 21 in Group 5 only), except those with a clear alternative explanation.
| Participants | Phase 1, Part 1, Group 1: Tafasitamab Monotherapy | Phase 1, Part 2, Group 2: Tafasitamab Plus Lenalidomide (LEN) | Phase 1, Part 2, Group 3: Tafasitamab Plus LEN | Phase 1, Part 2, Group 4a: Tafasitamab Plus Parsaclisib | Phase 1, Part 2, Group 5: Tafasitamab Plus LEN Plus R-CHOP |
|---|---|---|---|---|---|
| Phase 1, Part 1 and Part 2 (Groups 3, 4a, and 5); Number of Participants With Any Dose-limiting Toxicity (DLT) | 0 | — | 1 | 0 | 1 |
OR=percentage of participants with a complete response/complete metabolic response (CR/CMR) or partial response/partial metabolic response (PR/PMR). CR: (1) target nodes/nodal masses of lymph nodes/extralymphatic sites regressed to ≤1.5 centimeters (cm) in the longest dimension transverse diameter of lesion (LDi); (2) absence of non-measured lesions; (3) organ enlargement regressed to normal; (4) no new lesions; (5) normal bone marrow morphology; if indeterminate, immunohistochemistry negative. PR: (1) lymph nodes/extralymphatic sites: ≥50% decrease in the sum of the product of perpendicular diameters for multiple lesions of up to 6 target measurable nodes/extranodal sites; (2) absent/regressed non-measured lesions, no increase; (3) organ enlargement; spleen regressed by \>50% in length beyond normal; (4) no new lesions.
| percentage of participants | Phase 2, Part 4, Group 6: Tafasitamab Plus LEN |
|---|---|
| Phase 2, Part 4: Objective Response (OR) as Determined by an Independent Review Committee (IRC) According to Lugano Criteria | 71.4 (57.9 to 82.6) |
Cmax was defined as the maximum observed plasma concentration of tafasitamab. Samples were collected as follows: Groups 1, 3, and 4a: Cycle 1 Day 1, preinfusion, immediately after tafasitamab infusion, 1 and 4 hours post-infusion (PI). Cycle 1 Day 2, 24 hours PI on Day 1. Cycle 1 Days 4, 8, 15, and 22, preinfusion; 1 hour PI. Cycles 2 and 3 Days 1, 22, preinfusion and 1 hour PI. Cycle 4 and beyond every 4 cycles (8, 12, etc.) Day 1, preinfusion. Safety follow-up/end of study visit, untimed sample. Group 2: Cycle 1 Days 1, 4, 8, and 15, preinfusion, 30 min PI. Cycles 2 and 3 Days 1 and 15, preinfusion and 30 min PI. Cycle 4-12 (every other cycle, i.e., Cycle 4, 6, 8, 12) Day 1, preinfusion and 30 min PI. Cycle 12 Day 28 and end of treatment, untimed sample. Group 5: Cycle 1 Day 1, preinfusion, immediately after tafasitamab infusion, 1 and 4 hours PI. Cycle 1 Day 2, 24 hours PI on Day 1. Cycle 1 Days 8 and 15, preinfusion and 1 hour PI. Cycles 2 and 3-6 Day 1, preinfusion and 1 hour PI.
Results for this outcome have not been posted.
Cmin was defined as the minimum observed plasma concentration of tafasitamab. Samples were collected as follows: Groups 1, 3, and 4a: Cycle 1 Day 1, preinfusion, immediately after tafasitamab infusion, 1 and 4 hours post-infusion (PI). Cycle 1 Day 2, 24 hours PI on Day 1. Cycle 1 Days 4, 8, 15, and 22, preinfusion; 1 hour PI. Cycles 2 and 3 Days 1, 22, preinfusion and 1 hour PI. Cycle 4 and beyond every 4 cycles (8, 12, etc.) Day 1, preinfusion. Safety follow-up/end of study visit, untimed sample. Group 2: Cycle 1 Days 1, 4, 8, and 15, preinfusion, 30 min PI. Cycles 2 and 3 Days 1 and 15, preinfusion and 30 min PI. Cycle 4-12 (every other cycle, i.e., Cycle 4, 6, 8, 12) Day 1, preinfusion and 30 min PI. Cycle 12 Day 28 and end of treatment, untimed sample. Group 5: Cycle 1 Day 1, preinfusion, immediately after tafasitamab infusion, 1 and 4 hours PI. Cycle 1 Day 2, 24 hours PI on Day 1. Cycle 1 Days 8 and 15, preinfusion and 1 hour PI. Cycles 2 and 3-6 Day 1, preinfusion and 1 hour PI.
Results for this outcome have not been posted.
Cmax was defined as the maximum observed plasma concentration of tafasitamab.
Results for this outcome have not been posted.
Cmin was defined as the minimum observed plasma concentration of tafasitamab.
Results for this outcome have not been posted.
CR: (1) target nodes/nodal masses of lymph nodes/extralymphatic sites regressed to ≤1.5 cm in the longest dimension transverse diameter of lesion (LDi); (2) absence of non-measured lesions; (3) organ enlargement regressed to normal; (4) no new lesions; (5) normal bone marrow morphology; if indeterminate, immunohistochemistry negative. PR: (1) lymph nodes/extralymphatic sites: ≥50% decrease in the sum of the product of perpendicular diameters for multiple lesions of up to 6 target measurable nodes/extranodal sites; (2) absent/regressed non-measured lesions, no increase; (3) organ enlargement; spleen regressed by \>50% in length beyond normal; (4) no new lesions.
Results for this outcome have not been posted.
The sum of the products of the longest perpendicular diameters (SPD) was calculated by summing the products of the two longest perpendicular diameters for each target lesion or any extranodal lesion. Percent reduction in SPD from baseline in up to 6 target measurable nodes and extranodal sites assessed by computed tomography as per investigator assessment of response according to the Lugano criteria was calculated per assessment, and the highest reduction was analyzed.
Results for this outcome have not been posted.
CR: (1) target nodes/nodal masses of lymph nodes/extralymphatic sites regressed to ≤1.5 cm in the longest dimension transverse diameter of lesion (LDi); (2) absence of non-measured lesions; (3) organ enlargement regressed to normal; (4) no new lesions; (5) normal bone marrow morphology; if indeterminate, immunohistochemistry negative.
Results for this outcome have not been posted.
DOR was defined as the time from the first documented CR/CMR or PR/PMR as determined by an IRC according to the Lugano criteria until the date of the first documented disease progression or death due to any cause, whichever occurred first. CR: (1) target nodes/nodal masses of lymph nodes/extralymphatic sites regressed to ≤1.5 cm in the longest dimension transverse diameter of lesion (LDi); (2) absence of non-measured lesions; (3) organ enlargement regressed to normal; (4) no new lesions; (5) normal bone marrow morphology; if indeterminate, immunohistochemistry negative. PR: (1) lymph nodes/extralymphatic sites: ≥50% decrease in the sum of the product of perpendicular diameters for multiple lesions of up to 6 target measurable nodes/extranodal sites; (2) absent/regressed non-measured lesions, no increase; (3) organ enlargement; spleen regressed by \>50% in length beyond normal; (4) no new lesions.
Results for this outcome have not been posted.
PFS was defined as the time from the date of the first dose of study treatment until the first documented disease progression as determined by an IRC according to the Lugano criteria or death due to any cause, whichever occurred first. Kaplan-Meier estimates indicate the percent probability of a participant being alive at the indicated time after treatment start.
Results for this outcome have not been posted.
Overall survival was defined as defined as the time from the first dose of study treatment until death due to any cause. Kaplan-Meier estimates indicate the percent probability of a participant being alive at the indicated time after treatment start.
Results for this outcome have not been posted.
OR=percentage of participants with a CR/CMR or PR/PMR. CR: (1) target nodes/nodal masses of lymph nodes/extralymphatic sites regressed to ≤1.5 cm in the longest dimension transverse diameter of lesion (LDi); (2) absence of non-measured lesions; (3) organ enlargement regressed to normal; (4) no new lesions; (5) normal bone marrow morphology; if indeterminate, immunohistochemistry negative. PR: (1) lymph nodes/extralymphatic sites: ≥50% decrease in the sum of the product of perpendicular diameters for multiple lesions of up to 6 target measurable nodes/extranodal sites; (2) absent/regressed non-measured lesions, no increase; (3) organ enlargement; spleen regressed by \>50% in length beyond normal; (4) no new lesions.
Results for this outcome have not been posted.
CR: (1) target nodes/nodal masses of lymph nodes/extralymphatic sites regressed to ≤1.5 cm in the longest dimension transverse diameter of lesion (LDi); (2) absence of non-measured lesions; (3) organ enlargement regressed to normal; (4) no new lesions; (5) normal bone marrow morphology; if indeterminate, immunohistochemistry negative.
Results for this outcome have not been posted.
DOR was defined as the time from the first documented CR/CMR or PR/PMR as determined by an IRC according to the Lugano criteria until the date of the first documented disease progression or death due to any cause, whichever occurred first. CR: (1) target nodes/nodal masses of lymph nodes/extralymphatic sites regressed to ≤1.5 cm in the longest dimension transverse diameter of lesion (LDi); (2) absence of non-measured lesions; (3) organ enlargement regressed to normal; (4) no new lesions; (5) normal bone marrow morphology; if indeterminate, immunohistochemistry negative. PR: (1) lymph nodes/extralymphatic sites: ≥50% decrease in the sum of the product of perpendicular diameters for multiple lesions of up to 6 target measurable nodes/extranodal sites; (2) absent/regressed non-measured lesions, no increase; (3) organ enlargement; spleen regressed by \>50% in length beyond normal; (4) no new lesions.
Results for this outcome have not been posted.
PFS was defined as the time from the date of the first dose of study treatment until the first documented disease progression as determined by an IRC according to the Lugano criteria or death due to any cause, whichever occurred first.
Results for this outcome have not been posted.
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE was defined as any new AE/worsening of an event from the first dose to 90 days (30 days until Amendment 3) after the last dose.
Results for this outcome have not been posted.
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. A TEAE was defined as any new AE/worsening of an event from the first dose to 90 days (30 days until Amendment 3) after the last dose. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 Grades 1 through 5. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.
Results for this outcome have not been posted.
Collected over up to approximately 4.5 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1, Part 1, Group 1: Tafasitamab monotherapyPhase 1, Part 1, Group 1: Tafasitamab Monotherapy | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Phase 1, Part 2, Group 2: Tafasitamab Plus Lenalidomide (LEN) | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Phase 1, Part 2, Group 3: Tafasitamab Plus LEN | 0/6 (0%) | 2/6 (33.3%) | 6/6 (100%) |
| Phase 1, Part 2, Group 4a: Tafasitamab Plus Parsaclisib | 0/6 (0%) | 1/6 (16.7%) | 6/6 (100%) |
| Phase 1, Part 2, Group 5: Tafasitamab Plus LEN Plus R-CHOP | 1/6 (16.7%) | 1/6 (16.7%) | 6/6 (100%) |
| Phase 2, Part 4, Group 6: Tafasitamab Plus LEN | 7/42 (16.7%) | 8/42 (19%) | 40/42 (95.2%) |
| Total | 8/72 (11.1%) | 12/72 (16.7%) | 70/72 (97.2%) |
| Event | Phase 1, Part 1, Group 1: Tafasitamab monotherapyPhase 1, Part 1, Group 1: Tafasitamab Monotherapy | Phase 1, Part 2, Group 2: Tafasitamab Plus Lenalidomide (LEN) | Phase 1, Part 2, Group 3: Tafasitamab Plus LEN | Phase 1, Part 2, Group 4a: Tafasitamab Plus Parsaclisib | Phase 1, Part 2, Group 5: Tafasitamab Plus LEN Plus R-CHOP | Phase 2, Part 4, Group 6: Tafasitamab Plus LEN | Total |
|---|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 2/42 | 3/72 |
| Depressed level of consciousnessNervous system disorders | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/42 | 1/72 |
| DiarrhoeaGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/42 | 1/72 |
| Liver disorderHepatobiliary disorders | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/42 | 1/72 |
| Optic ischaemic neuropathyEye disorders | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/42 | 1/72 |
| AnaemiaBlood and lymphatic system disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/42 | 1/72 |
| Atrial fibrillationCardiac disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/42 | 1/72 |
| CholelithiasisHepatobiliary disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/42 | 1/72 |
| Herpes zosterInfections and infestations | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/42 | 1/72 |
| MalaiseGeneral disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/42 | 1/72 |
| Event | Phase 1, Part 1, Group 1: Tafasitamab monotherapyPhase 1, Part 1, Group 1: Tafasitamab Monotherapy | Phase 1, Part 2, Group 2: Tafasitamab Plus Lenalidomide (LEN) | Phase 1, Part 2, Group 3: Tafasitamab Plus LEN | Phase 1, Part 2, Group 4a: Tafasitamab Plus Parsaclisib | Phase 1, Part 2, Group 5: Tafasitamab Plus LEN Plus R-CHOP | Phase 2, Part 4, Group 6: Tafasitamab Plus LEN | Total |
|---|---|---|---|---|---|---|---|
| White blood cell count decreasedInvestigations | 1/6 | 2/6 | 2/6 | 1/6 | 6/6 | 2/42 | 14/72 |
| AnaemiaBlood and lymphatic system disorders | 0/6 | 1/6 | 2/6 | 1/6 | 5/6 | 4/42 | 13/72 |
| Neutrophil count decreasedInvestigations | 0/6 | 3/6 | 3/6 | 3/6 | 5/6 | 11/42 | 25/72 |
| DiarrhoeaGastrointestinal disorders | 0/6 | 1/6 | 3/6 | 4/6 | 0/6 | 16/42 | 24/72 |
| AlopeciaSkin and subcutaneous tissue disorders | 0/6 | 0/6 | 0/6 | 0/6 | 3/6 | 0/42 | 3/72 |
| Back painMusculoskeletal and connective tissue disorders | 0/6 | 0/6 | 0/6 | 0/6 | 3/6 | 2/42 | 5/72 |
| ConstipationGastrointestinal disorders | 1/6 | 0/6 | 1/6 | 0/6 | 3/6 | 12/42 | 17/72 |
| Decreased appetiteMetabolism and nutrition disorders | 0/6 | 1/6 | 3/6 | 0/6 | 0/6 | 4/42 | 8/72 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/6 | 0/6 | 0/6 | 0/6 | 3/6 | 0/42 | 3/72 |
| Lymphocyte count decreasedInvestigations | 1/6 | 1/6 | 1/6 | 1/6 | 3/6 | 2/42 | 9/72 |
| Age, Continuous(years) | Phase 1, Part 1, Group 1: Tafasitamab Monotherapy | Phase 1, Part 2, Group 2: Tafasitamab Plus Lenalidomide (LEN) | Phase 1, Part 2, Group 3: Tafasitamab Plus LEN | Phase 1, Part 2, Group 4a: Tafasitamab Plus Parsaclisib | Phase 1, Part 2, Group 5: Tafasitamab Plus LEN Plus R-CHOP | Phase 2, Part 4, Group 6: Tafasitamab Plus LEN | Total |
|---|---|---|---|---|---|---|---|
| Mean | 72.0 ± 4.98 | 79.0 ± 4.47 | 73.2 ± 7.47 | 68.5 ± 9.81 | 66.8 ± 5.42 | 72.5 ± 6.38 | 72.2 ± 6.86 |
| Sex: Female, Male(Participants) | Phase 1, Part 1, Group 1: Tafasitamab Monotherapy | Phase 1, Part 2, Group 2: Tafasitamab Plus Lenalidomide (LEN) | Phase 1, Part 2, Group 3: Tafasitamab Plus LEN | Phase 1, Part 2, Group 4a: Tafasitamab Plus Parsaclisib | Phase 1, Part 2, Group 5: Tafasitamab Plus LEN Plus R-CHOP | Phase 2, Part 4, Group 6: Tafasitamab Plus LEN | Total |
|---|---|---|---|---|---|---|---|
| Female | 4 | 4 | 3 | 5 | 4 | 23 | 43 |
| Male | 2 | 2 | 3 | 1 | 2 | 19 | 29 |
| Race/Ethnicity, Customized(Participants) | Phase 1, Part 1, Group 1: Tafasitamab Monotherapy | Phase 1, Part 2, Group 2: Tafasitamab Plus Lenalidomide (LEN) | Phase 1, Part 2, Group 3: Tafasitamab Plus LEN | Phase 1, Part 2, Group 4a: Tafasitamab Plus Parsaclisib | Phase 1, Part 2, Group 5: Tafasitamab Plus LEN Plus R-CHOP | Phase 2, Part 4, Group 6: Tafasitamab Plus LEN | Total |
|---|---|---|---|---|---|---|---|
| Asian | 6 | 6 | 6 | 6 | 6 | 42 | 72 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.
Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.
Data sharing details ↗ · www.incyte.com
Ran from Dec 2020 to primary completion in Jul 2025, 54 months.
Results were first posted in Oct 2026, 1 year 3 months after primary completion.
Of 51 industry-sponsored phase 1/2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 54 and three quarters within 99. This study's 54 months is below that.
Counting every sponsor, half of 108 studies reached it within 70 months; a quarter within 50 and three quarters within 98.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tafasitamab
Lymphoma, Large B-Cell, Diffuse →